{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T08:58:54Z","timestamp":1772009934511,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s13555-025-01599-5","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T02:59:28Z","timestamp":1765508368000},"page":"953-976","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bimekizumab Efficacy and Safety in Patients with Psoriatic Arthritis with Substantial Skin and Nail Psoriasis to 1\u00a0Year"],"prefix":"10.1007","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct03895203","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03896581","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04009499","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8513-550X","authenticated-orcid":false,"given":"Diamant","family":"Tha\u00e7i","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Asahina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolf-Henning","family":"Boehncke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice B.","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard B.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Edens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Ink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajan","family":"Bajracharya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Coarse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"issue":"1","key":"1599_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.7861\/clinmedicine.17-1-65","volume":"17","author":"LC Coates","year":"2017","unstructured":"Coates LC, Helliwell PS. Psoriatic arthritis: state of the art review. Clin Med (Lond). 2017;17(1):65\u201370.","journal-title":"Clin Med (Lond)"},{"issue":"10136","key":"1599_CR2","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","volume":"391","author":"DJ Veale","year":"2018","unstructured":"Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018;391(10136):2273\u201384.","journal-title":"Lancet"},{"issue":"10","key":"1599_CR3","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957\u201370.","journal-title":"N Engl J Med"},{"issue":"8","key":"1599_CR4","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465\u201379.","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"1599_CR5","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.3899\/jrheum.160904","volume":"44","author":"AM Orbai","year":"2017","unstructured":"Orbai AM, de Wit M, Mease PJ, et al. Updating the Psoriatic Arthritis (PsA) core domain set: a report from the PsA workshop at OMERACT 2016. J Rheumatol. 2017;44(10):1522\u20138.","journal-title":"J Rheumatol"},{"issue":"8","key":"1599_CR6","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665\u201373.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"1599_CR7","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/ard-2024-225531","volume":"83","author":"L Gossec","year":"2024","unstructured":"Gossec L, Kerschbaumer A, Ferreira RJO, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024;83(6):706\u201319.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1599_CR8","first-page":"952","volume":"40","author":"P Nash","year":"2022","unstructured":"Nash P, Mease PJ, Kirkham B, et al. Secukinumab provides sustained improvement in nail psoriasis, signs and symptoms of psoriatic arthritis and low rate of radiographic progression in patients with concomitant nail involvement: 2-year results from the phase\u00a0III FUTURE 5 study. Clin Exp Rheumatol. 2022;40(5):952\u20139.","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"1599_CR9","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1093\/rheumatology\/keh198","volume":"43","author":"L Williamson","year":"2004","unstructured":"Williamson L, Dalbeth N, Dockerty JL, Gee BC, Weatherall R, Wordsworth BP. Extended report: nail disease in psoriatic arthritis\u2013clinically important, potentially treatable and often overlooked. Rheumatology. 2004;43(6):790\u20134.","journal-title":"Rheumatology"},{"issue":"4","key":"1599_CR10","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3899\/jrheum.190923","volume":"48","author":"PJ Mease","year":"2021","unstructured":"Mease PJ, Liu M, Rebello S, et al. Association of nail psoriasis with disease activity measures and impact in psoriatic arthritis: data from the Corrona Psoriatic Arthritis\/Spondyloarthritis Registry. J Rheumatol. 2021;48(4):520\u20136.","journal-title":"J Rheumatol"},{"issue":"3","key":"1599_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2023.105534","volume":"90","author":"JA Walsh","year":"2023","unstructured":"Walsh JA, Ogdie A, Michaud K, et al. Impact of key manifestations of psoriatic arthritis on patient quality of life, functional status, and work productivity: Findings from a real-world study in the United States and Europe. Jt Bone Spine. 2023;90(3):105534.","journal-title":"Jt Bone Spine"},{"issue":"Suppl 1","key":"1599_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000316169","volume":"221","author":"R Baran","year":"2010","unstructured":"Baran R. The burden of nail psoriasis: an introduction. Dermatology. 2010;221(Suppl 1):1\u20135.","journal-title":"Dermatology"},{"issue":"2","key":"1599_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00296-025-05791-w","volume":"45","author":"C Pitzalis","year":"2025","unstructured":"Pitzalis C, Myall N, Dey M, Kouranloo K. Severity of skin disease strongly correlates with quality of life in people with psoriatic arthritis: a systematic review. Rheumatol Int. 2025;45(2):39.","journal-title":"Rheumatol Int"},{"issue":"5","key":"1599_CR14","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1007\/s12325-021-01698-7","volume":"38","author":"M Skornicki","year":"2021","unstructured":"Skornicki M, Prince P, Suruki R, Lee E, Louder A. Clinical burden of concomitant joint disease in psoriasis: a US-linked claims and electronic health records database analysis. Adv Ther. 2021;38(5):2458\u201371.","journal-title":"Adv Ther"},{"key":"1599_CR15","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.3389\/fimmu.2020.01894","volume":"11","author":"R Adams","year":"2020","unstructured":"Adams R, Maroof A, Baker T, et al. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. Front Immunol. 2020;11:1894.","journal-title":"Front Immunol"},{"issue":"1","key":"1599_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003855","volume":"10","author":"LC Coates","year":"2024","unstructured":"Coates LC, Landew\u00e9 R, McInnes IB, et al. Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase\u00a0III BE\u00a0COMPLETE study and its open-label extension BE\u00a0VITAL. RMD Open. 2024;10(1):e003855.","journal-title":"RMD Open"},{"issue":"10370","key":"1599_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","volume":"401","author":"IB McInnes","year":"2023","unstructured":"McInnes IB, Asahina A, Coates LC, et al. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase\u00a03 trial (BE\u00a0OPTIMAL). Lancet. 2023;401(10370):25\u201337.","journal-title":"Lancet"},{"issue":"10370","key":"1599_CR18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","volume":"401","author":"JF Merola","year":"2023","unstructured":"Merola JF, Landew\u00e9 R, McInnes IB, et al. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-\u03b1 inhibitors: a randomised, double-blind, placebo-controlled, phase\u00a03 trial (BE\u00a0COMPLETE). Lancet. 2023;401(10370):38\u201348.","journal-title":"Lancet"},{"issue":"11","key":"1599_CR19","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1136\/ard-2023-224431","volume":"82","author":"CT Ritchlin","year":"2023","unstructured":"Ritchlin CT, Coates LC, McInnes IB, et al. Bimekizumab treatment in biologic DMARD-na\u00efve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase\u00a0III, randomised, placebo-controlled, active reference BE\u00a0OPTIMAL study. Ann Rheum Dis. 2023;82(11):1404\u201314.","journal-title":"Ann Rheum Dis"},{"issue":"10273","key":"1599_CR20","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","volume":"397","author":"K Reich","year":"2021","unstructured":"Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE\u00a0VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase\u00a03 trial. Lancet. 2021;397(10273):487\u201398.","journal-title":"Lancet"},{"issue":"2","key":"1599_CR21","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa2102383","volume":"385","author":"K Reich","year":"2021","unstructured":"Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med. 2021;385(2):142\u201352.","journal-title":"N Engl J Med"},{"issue":"2","key":"1599_CR22","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa2102388","volume":"385","author":"RB Warren","year":"2021","unstructured":"Warren RB, Blauvelt A, Bagel J, et al. Bimekizumab versus adalimumab in plaque psoriasis. N Engl J Med. 2021;385(2):130\u201341.","journal-title":"N Engl J Med"},{"issue":"4","key":"1599_CR23","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/bjd\/ljad429","volume":"190","author":"KB Gordon","year":"2024","unstructured":"Gordon KB, Langley RG, Warren RB, et al. Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3\u00a0years of treatment in randomized phase\u00a0III trials. Br J Dermatol. 2024;190(4):477\u201385.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1599_CR24","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1093\/bjd\/ljad035","volume":"188","author":"B Strober","year":"2023","unstructured":"Strober B, Tada Y, Mrowietz U, et al. Bimekizumab maintenance of response through 3\u00a0years in patients with moderate-to-severe plaque psoriasis: results from the BE\u00a0BRIGHT open-label extension trial. Br J Dermatol. 2023;188(6):749\u201359.","journal-title":"Br J Dermatol"},{"issue":"12","key":"1599_CR25","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1007\/s13555-024-01295-w","volume":"14","author":"JF Merola","year":"2024","unstructured":"Merola JF, Gottlieb AB, Pinter A, et al. Bimekizumab efficacy in high-impact areas: pooled 2-year analysis in scalp, nail, and palmoplantar psoriasis from phase\u00a03\/3b randomized controlled trials. Dermatol Ther (Heidelb). 2024;14(12):3291\u2013306.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1599_CR26","unstructured":"European Medicines Agency. Summary of products characteristics. Bimzelx 160\u00a0mg solution. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/bimzelx-epar-product-information_en.pdf. Last Accessed 13 Sept 2024."},{"key":"1599_CR27","unstructured":"Food and Drug Administration. Highlights of prescribing information. BIMZELX. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761151s010lbl.pdf. Accessed 4 Aug 2025."},{"key":"1599_CR28","unstructured":"KEGG: Kyoto Encyclopedia of Genes and Genomes. Prescription drugs: Bimzelx. https:\/\/www.kegg.jp\/medicus-bin\/japic_med?japic_code=00070181. Accessed 19 Nov 2024."},{"key":"1599_CR29","doi-asserted-by":"crossref","unstructured":"Mease PJ, Antoni CE, Gladman DD, Taylor WJ. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis. 2005;64 Suppl 2(Suppl 2):ii49\u201354.","DOI":"10.1136\/ard.2004.034165"},{"issue":"4","key":"1599_CR30","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000250839","volume":"157","author":"T Fredriksson","year":"1978","unstructured":"Fredriksson T, Pettersson U. Severe psoriasis\u2013oral therapy with a new retinoid. Dermatologica. 1978;157(4):238\u201344.","journal-title":"Dermatologica"},{"issue":"1","key":"1599_CR31","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/ard.2008.102053","volume":"69","author":"LC Coates","year":"2010","unstructured":"Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69(1):48\u201353.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1599_CR32","first-page":"365","volume":"28","author":"H Nagasawa","year":"2010","unstructured":"Nagasawa H, Kameda H, Sekiguchi N, Amano K, Takeuchi T. Normalisation of physical function by infliximab in patients with RA: factors associated with normal physical function. Clin Exp Rheumatol. 2010;28(3):365\u201372.","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"1599_CR33","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1136\/ard.2009.122259","volume":"69","author":"M Schoels","year":"2010","unstructured":"Schoels M, Aletaha D, Funovits J, Kavanaugh A, Baker D, Smolen JS. Application of the DAREA\/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis. 2010;69(8):1441\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1599_CR34","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s41687-019-0094-5","volume":"3","author":"D Cella","year":"2019","unstructured":"Cella D, Wilson H, Shalhoub H, et al. Content validity and psychometric evaluation of functional assessment of chronic illness therapy-fatigue in patients with psoriatic arthritis. J Patient Rep Outcomes. 2019;3(1):5.","journal-title":"J Patient Rep Outcomes"},{"issue":"11","key":"1599_CR35","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.3899\/jrheum.110546","volume":"38","author":"PJ Mease","year":"2011","unstructured":"Mease PJ, Woolley JM, Bitman B, Wang BC, Globe DR, Singh A. Minimally important difference of health assessment questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction. J Rheumatol. 2011;38(11):2461\u20135.","journal-title":"J Rheumatol"},{"issue":"6","key":"1599_CR36","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1136\/annrheumdis-2014-205207","volume":"73","author":"L Gossec","year":"2014","unstructured":"Gossec L, de Wit M, Kiltz U, et al. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis. 2014;73(6):1012\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1599_CR37","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1136\/annrheumdis-2013-204948","volume":"74","author":"MH Buch","year":"2015","unstructured":"Buch MH, Silva-Fernandez L, Carmona L, et al. Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. Ann Rheum Dis. 2015;74(6):963\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1599_CR38","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/1756-185X.14442","volume":"26","author":"G Cengiz","year":"2023","unstructured":"Cengiz G, Nas K, Keskin Y, et al. The impact of nail psoriasis on disease activity, quality of life, and clinical variables in patients with psoriatic arthritis: a cross-sectional multicenter study. Int J Rheum Dis. 2023;26(1):43\u201350.","journal-title":"Int J Rheum Dis"},{"issue":"11","key":"1599_CR39","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1136\/annrheumdis-2012-203018","volume":"72","author":"KM Fagerli","year":"2013","unstructured":"Fagerli KM, Lie E, van der Heijde D, et al. Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study. Ann Rheum Dis. 2013;72(11):1840\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1599_CR40","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1111\/ced.15237","volume":"47","author":"Y Xie","year":"2022","unstructured":"Xie Y, Liu Y. Does previous use of tumour necrosis inhibitors change the therapeutic effect of interleukin (IL)-17 or IL-12\/23 inhibitors on psoriasis and psoriatic arthritis? Results of a systematic review. Clin Exp Dermatol. 2022;47(9):1627\u201335.","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"1599_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001321","volume":"6","author":"A Ogdie","year":"2020","unstructured":"Ogdie A, Michaud K, Nowak M, et al. Patient\u2019s experience of psoriatic arthritis: a conceptual model based on qualitative interviews. RMD Open. 2020;6(3):e001321.","journal-title":"RMD Open"},{"key":"1599_CR42","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X241288071","volume":"16","author":"LE Kristensen","year":"2024","unstructured":"Kristensen LE, Tillett W, Nash P, et al. Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase\u00a0III studies. Ther Adv Musculoskelet Dis. 2024;16:1759720x241288071.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"8","key":"1599_CR43","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1080\/14712598.2024.2385020","volume":"24","author":"R Queiro","year":"2024","unstructured":"Queiro R, Alonso S, Pinto-Tasende JA. The nail in psoriatic arthritis: new insights into prognosis and treatment. Expert Opin Biol Ther. 2024;24(8):715\u20137.","journal-title":"Expert Opin Biol Ther"},{"key":"1599_CR44","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.2147\/CCID.S467832","volume":"17","author":"A Zabotti","year":"2024","unstructured":"Zabotti A, Cabas N, Giovannini I, et al. Bimekizumab in biologics-refractory psoriatic arthritis: a real-life analysis from a combined dermatology-rheumatology clinic. Clin Cosmet Investig Dermatol. 2024;17:1553\u20136.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"1","key":"1599_CR45","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1111\/ijd.17927","volume":"64","author":"G Caldarola","year":"2025","unstructured":"Caldarola G, Dattola A, Bernardini N, et al. Effectiveness of bimekizumab in psoriatic arthritis: a multicenter real-life study with clinical and ultrasound evaluation in the Lazio region, Italy. Int J Dermatol.\u00a02025;64(11):2038\u201344\u00a0https:\/\/doi.org\/10.1111\/ijd.17927.","journal-title":"Int J Dermatol"},{"issue":"5","key":"1599_CR46","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s40744-025-00784-4","volume":"12","author":"A Zabotti","year":"2025","unstructured":"Zabotti A, Cabas N, De Martino M, et al. Real-world effectiveness of bimekizumab in predominantly difficult-to-treat patients with psoriatic arthritis followed in a combined dermatology-rheumatology clinic: a 24-week multicenter study. Rheumatol Ther.\u00a02025;12(5):961\u2013973\u00a0https:\/\/doi.org\/10.1007\/s40744-025-00784-4.","journal-title":"Rheumatol Ther"},{"issue":"2","key":"1599_CR47","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","volume":"9","author":"RH Dworkin","year":"2008","unstructured":"Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9(2):105\u201321.","journal-title":"J Pain"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01599-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01599-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01599-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T08:04:27Z","timestamp":1772006667000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01599-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1599"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01599-5","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"25 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Diamant Tha\u00e7i: Investigator and\/or consultant\/advisor for AbbVie, Almirall, Amgen, BMS, Boehringer Ingelheim, Celltrion, Eli Lilly and Company, Galderma, Johnsson and Johnsson, Kyowa Kirin, LEO Pharma, L\u2019Or\u00e9al, New Bridge, Novartis, Pfizer, Regeneron, Samsung, Sanofi, Takeda, Target-RWE, UCB and Vichy; received grants from AbbVie, LEO Pharma and Novartis. Akihiko Asahina: Honoraria and\/or research grants from AbbVie, Amgen, BMS, Boehringer Ingelheim, Eisai, Eli Lilly and Company, Janssen, Kyowa Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe Pharma, Novartis, Pfizer, Sun Pharma, Taiho Pharma, Torii Pharmaceutical Co. and UCB. Wolf-Henning Boehncke: Received honoraria as a speaker and\/or advisor from AbbVie, Almirall, BMS, Eli Lilly and Company, Janssen, LEO Pharma, Novartis and UCB. Alice B. Gottlieb: At the time of manuscript preparation Alice B. Gottlieb was at Icahn School of Medicine at Mount Sinai, Alice B. Gottlieb\u2019s affiliation is now Department of Dermatology, UT Southwestern Medical Center, Dallas, Texas, USA. Received research\/educational grants from BMS, Janssen, MoonLake Immunotherapeutics and UCB (all paid to Mount Sinai School of Medicine until 1 May\u00a02025). At UTSW Alice B. Gottlieb is Sub I on studies from BMS and Janssen; received honoraria\/speaker fees as an advisory board member and consultant for Amgen, BMS, Eli Lilly and Company, Janssen, Novartis, Oruka, Sanofi, Sun Pharma, Takeda, Teva and UCB. Mark Lebwohl: Employee of Mount Sinai and receives research funds from Abbvie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Cara Therapeutics, Dermavant Sciences, Eli Lilly and Company, Incyte, Inozyme, Janssen Research & Development, LLC, Ortho Dermatologics, Pfizer, Sanofi-Regeneron and UCB; consultant for Almirall, AltruBio Inc., AnaptysBio, Apogee, Arcutis Inc., AstraZeneca, Atomwise, Avotres Therapeutics, BMS, Boehringer Ingelheim, Brickell Biotech, Castle Biosciences, Celltrion, CorEvitas, Dermavant Sciences, EPI, Evommune Inc., Facilitation of International Dermatology Education, Forte Biosciences, Foundation for Research and Education in Dermatology, Galderma, Genentech, Incyte, LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Sanofi-Regeneron, Seanergy, Strata, Takeda, Trevi and Verrica. Mark Lebwohl is an Editorial Board member of\n                      Dermatology and Therapy.\n                      Mark Lebwohl was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Richard B. Warren: Consulting fees from AbbVie, Almirall, Amgen, Arena, Astellas, Avillion, Biogen, BMS, Boehringer Ingelheim, Celgene, DICE Therapeutics, Eli Lilly and Company, GSK, Janssen, LEO Pharma, Meiji Pharma, Novartis, Pfizer, RAPT Therapeutics, Sanofi, Sun Pharma, UCB and Union; research grants to his institution from AbbVie, Almirall, Amgen, Celgene, Eli Lilly and Company, Janssen, LEO Pharma, Novartis, Pfizer and UCB; honoraria from AbbVie, Almirall, BMS, Eli Lilly and Company, Galderma, Janssen and Novartis. Richard B. Warren is an Editor-in-Chief of\n                      Dermatology and Therapy.\n                      Richard B. Warren was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Heather Edens: Employee of UCB; shareholder of Abbott and UCB. Barbara Ink: Employee of UCB; shareholder of AbbVie, GSK and UCB. Rajan Bajracharya and Jason Coarse: Employees and shareholders of UCB. Joseph F. Merola: Consultant and\/or investigator for AbbVie, Amgen, AstraZeneca, Biogen, BMS, Boehringer Ingelheim, Dermavant, Eli Lilly and Company, Incyte, Janssen, LEO Pharma, MoonLake Immunotherapeutics, Novartis, Pfizer, Sanofi-Regeneron, Sun Pharma and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The BE\u00a0OPTIMAL and BE\u00a0COMPLETE trials and their OLE study were conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonisation Guidance for Good Clinical Practice. Ethics approval was obtained from the relevant institutional review boards at participating sites. Separate ethics approval for the current study was not obtained, as it was a post hoc analysis.All participants provided written informed consent in accordance with local requirements, with additional written informed consent required for enrolment in the OLE study. All the results presented in this article are in aggregate form, and no personally identifiable information was used for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}